Dr. rer. nat. Christopher Lischer

Department of Dermatology Department of Medicine 5 – Haematology and Oncology

Gene network-based and ensemble modeling-based selection of tumor-associated antigens with a predicted low risk of tissue damage for targeted immunotherapy (2024) Lischer C, Eberhardt M, Flamann C, Berges J, Güse E, Wessely A, Weich A, et al. Journal article Mutations in the splicing factor SF3B1 are linked to frequent emergence of HLA-DRlow/neg monocytes in lower-risk myelodysplastic neoplasms (2024) Winter S, Schneider M, Oelschlaegel U, Maggioni G, Riva E, Raddi MG, Bencini S, et al. Journal article Breaking barriers: NEK2 inhibition shines in multiple myeloma treatment (2023) Lischer C, Bruns H Journal article Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy (2023) Reimann H, Kremer A, Blumenberg V, Schmidt K, Aigner M, Jacobs B, Eisenhauer N, et al. Journal article, Letter Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT (2023) Karl F, Liang C, Böttcher-Loschinski R, Stoll A, Flamann C, Richter S, Lischer C, et al. Journal article Melanoma 2.0. Skin cancer as a paradigm for emerging diagnostic technologies, computational modelling and artificial intelligence (2022) Vera J, Lai X, Baur A, Erdmann M, Gupta S, Gutta C, Heinzerling L, et al. Journal article, Review article Eine übermäßige Phagozytose von Myelomzellen induziert Pyroptose in Myelom-assoziierten Makrophagen und beeinträchtigt die Wirksamkeit therapeutischer Antikörper (2022) Flamann C, Biedermann A, Mougiakakos D, Bitterer K, Karg K, Bittenbring J, Büttner-Herold M, et al. Conference contribution Increased CD47 expression inhibits phagocytosis of alloreactive donor T cells after allo-HSCT (2022) Flamann C, Matos C, Kreutz M, Shaikh H, Beilhack A, Büttner-Herold M, Lischer C, et al. Conference contribution Single-cell Transcriptome Analysis and clonal Kinetics in a Patient after CD19.CAR-T Cell Therapy (2022) Lischer C, Eisenhauer N, Aigner M, Jacobs B, Schletter M, Gebhard C, Rehli M, et al. Conference contribution SOX10-based drug repurposing identifies novel therapeutic targets in uveal melanoma (2022) Wessely A, Kammerbauer C, Lischer C, Weich A, Vera J, Berking C, Heppt M Conference contribution